SharePoint
A- A A+

For Patients & Visitors

Find a Doctor

Find a Doctor

Dr Raghav Sundar

Designations:
  • Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS(S'pore), MRCP(UK), MMed(Int Med), MCI, FAMS (Oncology), PhD
Specialties:
Medical Oncology
Special Interests:
Precision Oncology and Biomarker Development, Gastrointestinal Cancers, Early Phase Drug Development, Chemotherapy Induced Peripheral Neuropathy

Biosketch

Dr Raghav Sundar is a clinician-scientist specialising in gastrointestinal oncology. He is a Consultant Medical Oncologist and Research Director in the Department of Haematology-Oncology, at the National University Cancer Institute, Singapore. He treats patients with gastrointestinal malignancies including colorectal, gastric and hepatobiliary malignancies. He specialises in experimental therapeutics and early phase clinical trials, and is a part of the Phase 1 clinical trials team. He underwent fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK. His research interest is in genomics and epigenetics of gastric cancer and tumors that metastasize to the peritoneum. He studies the interaction between the tumor epigenome and the immune microenvironment. His work has identified predictive biomarkers of systemic therapy in gastric cancer as well as potential therapeutic targets. His studies incorporate contemporary technology such as spatial transcriptomics and machine-learning. Another area of research interest in chemotherapy induced peripheral neuropathy. As a translational clinician-scientist his works arches across several domains, collaborating with engineers, bioinformaticians, laboratory scientists, pharmaceutical and industry partners. He has published over 80 manuscripts, in high impact journals such as Cancer Discovery, Journal of Clinical Oncology, British Medical Journal and Gut.

Leadership Positions

Research Director (April 2022 - Present) – National University Cancer Institute, Singapore, National University Health System.

Assistant Research Director (November 2020 – March 2022) – National University Cancer Institute, Singapore, National University Health System.

Chief Senior Resident (Jan 2013 to July 2013) – Department of Haematology-Oncology, National University Health System.

Chief Resident (Academic) (November 2011 to May 2012) - University Medical Centre, National University Health System (First Academic Chief Resident in Singapore)

Chief Resident (May 2011 to October 2011) – University Medical Centre, National University Health System 

Awards

  1. NUHS Mochtar Riady Pinnacle Award Young Achiever (2022)
  2. National University of Singapore - Too Joon Chew PhD Prize
  3. Singapore Medical Association Charity Fund Outstanding Mentor Award (2022)
  4. National University of Singapore Yong Loo Lin School of Medicine Best Graduate Research Publication Award (2021) – NUS
  5. National Medical Research Council Transition Award (2021) 
  6. Wong Hock Boon Society - Singapore Medical AssociationSMA Charity Fund Outstanding Mentor Award (2021)
  7. National Medical Research Council Research PhD Fellowship (2018)
  8. Conquer Cancer Foundation of ASCO Merit Award (2017) – ASCO Annual Meeting, Chicago, 2017 

Journals & Publications

    1. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. Gwee YX, Chia DKA, So J, Ceelen W, Yong WP, Tan P, Ong CJ, Sundar R. J Clin Oncol. 2022 Aug 20;40(24):2830. (Impact Factor: 51)
    2. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. Lee ARYB, Wong SY, Chai LYA, …, Tan BKJ, Chan YH, Sundar R*, Soon YY. BMJ. 2022 Mar 2;376:e068632. *corresponding author (Impact Factor: 93)
    3. Low PD-L1 Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Escophageal Adenocarcinoma. Zhao JJ., Yap WT, Chan YK, Tan BKJ, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar RJ Clin Oncol. 2022 Feb 1;40(4):392-402. (Impact Factor: 51)
    4. Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Kumar V*, Ramnarayanan K*, Sundar R*, Padmanbahan N*, …, Tan P. Cancer Discov. 2022 Mar 1;12(3):670-691. *Joint first authors (Impact Factor: 40)
    5. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Sundar R*, Huang KK, Kumar V, Ramnarayanan K, …, Tan P*. Gut. 2022 Jul;71(7):1277-1288. *joint corresponding (Impact Factor: 32)
    6. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, …, Tan P. Gut. Gut. 2022 Apr;71(4):676-685. (Impact Factor: 32)
    7. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Sundar R, Liu D, Hutchins G, .. Tan P, Grabsch H. Gut. 2021 Oct;70(10):1823-1832. (Impact Factor: 32)
    8. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Sundar R, Huang KK, Qamra A, … Tan P. Ann Oncol. 2019 Mar 1;30(3):424-430. (Impact Factor: 50)
    9. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Basu B*, Krebs MG*, Sundar R*, et al. Ann Oncol. 2018 Sep 1;29(9):1918-1925. *Joint first authors (Impact Factor: 50)